Id |
Subject |
Object |
Predicate |
Lexical cue |
T34 |
0-42 |
Sentence |
denotes |
Evasion of Innate Sensing by Coronaviruses |
T35 |
43-186 |
Sentence |
denotes |
As these cytokines represent a major barrier to viral infection, CoVs have evolved several mechanisms to inhibit IFN-I induction and signaling. |
T36 |
187-369 |
Sentence |
denotes |
Numerous studies have demonstrated that SARS-CoV-1 suppresses IFN release in vitro and in vivo (Cameron et al., 2012, Minakshi et al., 2009, Siu et al., 2009, Wathelet et al., 2007). |
T37 |
370-573 |
Sentence |
denotes |
SARS-CoV-2 likely achieves a similar effect, as suggested by the lack of robust type I/III IFN signatures from infected cell lines, primary bronchial cells, and a ferret model (Blanco-Melo et al., 2020). |
T38 |
574-723 |
Sentence |
denotes |
In fact, patients with severe COVID-19 demonstrate remarkably impaired IFN-I signatures as compared to mild or moderate cases (Hadjadj et al., 2020). |
T39 |
724-933 |
Sentence |
denotes |
As is often the case, there are multiple mechanisms of evasion for CoVs, with viral factors antagonizing each step of the pathway from PRR sensing and cytokine secretion to IFN signal transduction (Figure 1 ). |
T40 |
934-1013 |
Sentence |
denotes |
Figure 1 Mechanisms of Host Innate Immune Response and Coronaviruses Antagonism |
T41 |
1014-1188 |
Sentence |
denotes |
Overview of innate immune sensing (left) and interferon signaling (right), annotated with the known mechanisms by which SARS-CoV-1 and MERS-CoV antagonize the pathways (red). |
T42 |
1189-1505 |
Sentence |
denotes |
CoV-mediated antagonism of innate immunity begins with evasion of PRR sensing. ssRNA viruses, like CoVs, form dsRNA intermediates during their replication, which can be detected by TLR3 in the endosome and RIG-I, MDA5, and PKR in the cytosol. ssRNA may also be detected by TLR7 or TLR8 and potentially RIG-I and PKR. |
T43 |
1506-1739 |
Sentence |
denotes |
CoVs are known to avoid PRR activation by either avoiding recognition altogether or antagonizing PRR action (Bouvet et al., 2010, Chen et al., 2009, Deng et al., 2017, Hackbart et al., 2020, Ivanov et al., 2004, Knoops et al., 2008). |
T44 |
1740-1881 |
Sentence |
denotes |
To evade PRRs, dsRNA is first shielded by membrane-bound compartments that form during viral replication of SARS-CoV-1 (Knoops et al., 2008). |
T45 |
1882-2171 |
Sentence |
denotes |
In addition, viral RNA is guanosine-capped and methylated at the 5′ end by CoVs non-structural proteins (NSPs) 10, 13, 14, and 16 (Bouvet et al., 2010, Chen et al., 2009, Ivanov et al., 2004), thereby resembling host mRNA to promote translation, prevent degradation, and evade RLR sensing. |
T46 |
2172-2373 |
Sentence |
denotes |
Finally, CoVs also encode an endoribonuclease, NSP15, that cleaves 5′ polyuridines formed during viral replication, which would otherwise be detected by MDA5 (Deng et al., 2017, Hackbart et al., 2020). |
T47 |
2374-2443 |
Sentence |
denotes |
CoVs have evolved additional strategies to impede activation of PRRs. |
T48 |
2444-2519 |
Sentence |
denotes |
SARS-CoV-1 N-protein prevents TRIM25 activation of RIG-I (Hu et al., 2017). |
T49 |
2520-2718 |
Sentence |
denotes |
Likewise, MERS-CoV NS4a, which itself binds dsRNA, impedes PKR activation (Comar et al., 2019, Rabouw et al., 2016) and inhibits PACT, an activator of RLRs (Niemeyer et al., 2013, Siu et al., 2014). |
T50 |
2719-2820 |
Sentence |
denotes |
Additionally, MERS-CoV NS4b antagonizes RNaseL, another activator of RLRs (Thornbrough et al., 2016). |
T51 |
2821-2860 |
Sentence |
denotes |
The role of other PRRs remains unclear. |
T52 |
2861-3015 |
Sentence |
denotes |
For example, SARS-CoV-1 papain-like protease (PLP) antagonizes STING, suggesting that self-DNA may also represent an important trigger (Sun et al., 2012). |
T53 |
3016-3104 |
Sentence |
denotes |
The extent to which SARS-CoV-2 homologs overlap in these functions is currently unknown. |
T54 |
3105-3362 |
Sentence |
denotes |
Following activation, RLR and TLRs induce signaling cascades, leading to the phosphorylation of transcription factors, such as NF-kB and the interferon-regulatory factor family (IRF), ultimately leading to transcription of IFN and proinflammatory cytokines. |
T55 |
3363-3557 |
Sentence |
denotes |
Although no experimental studies have delineated the precise functions of SARS-CoV-2 proteins, proteomic studies have demonstrated interactions between viral proteins and PRR signaling cascades. |
T56 |
3558-3779 |
Sentence |
denotes |
SARS-CoV-2 ORF9b indirectly interacts with the signaling adaptor MAVS via its association with Tom70 (Gordon et al., 2020), consistent with prior reports that SARS-CoV-1 ORF9b suppresses MAVS signaling (Shi et al., 2014). |
T57 |
3780-3942 |
Sentence |
denotes |
Furthermore, SARS-CoV-2 NSP13 interacts with signaling intermediate TBK1, and NSP15 is associated with RNF41, an activator of TBK1 and IRF3 (Gordon et al., 2020). |
T58 |
3943-4085 |
Sentence |
denotes |
Similarly, SARS-CoV-1 M protein is known to inhibit the TBK1 signaling complex (Siu et al., 2009), as does MERS-CoV ORF4b (Yang et al., 2015). |
T59 |
4086-4255 |
Sentence |
denotes |
Other proteins, including SARS-CoV-1 PLP, N, ORF3b, and ORF6, block IRF3 phosphorylation and nuclear translocation (Devaraj et al., 2007, Kopecky-Bromberg et al., 2007). |
T60 |
4256-4296 |
Sentence |
denotes |
NF-kB is also inhibited by CoV proteins. |
T61 |
4297-4423 |
Sentence |
denotes |
These include SARS-CoV-1 PLP (Frieman et al., 2009) and MERS-CoV ORF4b and ORF5 (Canton et al., 2018, Menachery et al., 2017). |
T62 |
4424-4654 |
Sentence |
denotes |
Finally, SARS-CoV-1 NSP1 (Huang et al., 2011a, Kamitani et al., 2009) and MERS-CoV NSP1 (Lokugamage et al., 2015) initiate general inhibition of host transcription and translation, thus limiting antiviral defenses nonspecifically. |
T63 |
4655-4876 |
Sentence |
denotes |
To prevent signaling downstream of IFN release, CoV proteins inhibit several steps of the signal transduction pathway that bridge the receptor subunits (IFNAR1 and IFNAR2) to the STAT proteins that activate transcription. |
T64 |
4877-5144 |
Sentence |
denotes |
For SARS-CoV-1, these mechanisms include IFNAR1 degradation by ORF3a (Minakshi et al., 2009), decreased STAT1 phosphorylation by NSP1 (Wathelet et al., 2007), and antagonism of STAT1 nuclear translocation by ORF6 (Frieman et al., 2007, Kopecky-Bromberg et al., 2007). |
T65 |
5145-5267 |
Sentence |
denotes |
However, SARS-CoV-2 ORF6 shares only 69% sequence homology with SARS-CoV-1, suggesting this function may not be conserved. |
T66 |
5268-5411 |
Sentence |
denotes |
In support of this notion, SARS-CoV-2 infection fails to limit STAT1 phosphorylation, unlike in SARS-CoV-1 infection (Lokugamage et al., 2020). |